60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
Frequently asked questions
What sector does 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) operate in?
60 Degrees Pharmaceuticals, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) current stock price?
As of the latest data, 60 Degrees Pharmaceuticals, Inc. Common Stock stock price is $0.87, with a previous close of $0.87. 60 Degrees Pharmaceuticals, Inc. Common Stock lost -$0.00 in the last trading session, representing a -0.25% loss.
What is 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) current market capitalization?
60 Degrees Pharmaceuticals, Inc. Common Stock market cap is approximately 3.05 million.
What is 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Earnings Per Share (EPS)?
The trailing EPS is -$2.49, and the forward EPS is -$3.58.
What is 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) EBITDA?
60 Degrees Pharmaceuticals, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.29 million.
Does 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) pay dividends?
No. 60 Degrees Pharmaceuticals, Inc. Common Stock does not pay a dividend.
How did 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) perform in its most recent earnings report?
In the last report (June 30, 2026), 60 Degrees Pharmaceuticals, Inc. Common Stock posted an EPS surprise of -21.62% and a revenue surprise of 12.38%.
What is 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) beta (volatility) score?
60 Degrees Pharmaceuticals, Inc. Common Stock has a beta of 2.537, indicating very high volatility compared to the market.
